Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress

Hypertension

Volumn 44, Issue 2, 2004, Pages 186-190

  Zhou, Ming Sheng ^a   Jaimes, Edgar A ^a   Raij, Leopoldo ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hypertension; Nitric oxide synthase; Oxidative stress; Sodium dependent; Statins

Indexed keywords

ANGIOTENSIN; ATORVASTATIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ISOPROSTANE DERIVATIVE; NITRIC OXIDE; STATINE DERIVATIVE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL REACTIVITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HYPERTENSION; MALE; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEINURIA; RAT; RECEPTOR DOWN REGULATION; SODIUM METABOLISM;

ANIMALS; AORTA; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HEART VENTRICLES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; OXIDATIVE STRESS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM, DIETARY;

EID: 3542998086     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000136395.06810.cf     Document Type: Article

References (39)

1. Randomised trial of cholesterol lowering in loss of 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
3. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149-1158.
4. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286.
5. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
6. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305.
7. Faggiotto A, Paoletti R. State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension. 1999;34:987-996.
8. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, Nickenig G, HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001; 37:1450-1457.
9. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31:225-231.
10. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol. 2002;40:611-617.
11. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res. 2002;91:173-179.
12. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation. 1997;96:2407-2413.
13. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension. 1997;29:235-241.
14. Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension. 1998;31:266-270.
15. Zhou MS, Adam AG, Jaimers EA, Raij L. In salt-sensitive hypertension increased superoxide production is linked to a functional upregulation of angiotensin II. Hypertension. 2003;42:945-951.
16. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension. 2003;41:592-597.
17. Inagaki K, Iwanaga Y, Sarai N, Onozawa Y, Takenaka H, Mochly-Rosen D, Kihara Y. Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKCε and PKCβ. J Mol Cell Cardiol. 2002;34:1377-1385.
18. Fujii S, Zhang L, Igarashi J, Kosaka H. L-arginine reverse p47phox and gp91phox expression induced by high salt in Dahl rats. Hypertension. 2003;42:1014-1020.
19. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37:767-773.
20. Szenfivanyi M, Jr., Zou AP, Mattson DL, Soares P, Moreno C, Roman RJ, Cowley AW, Jr. Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2002;283:R266-R272.
21. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003; 284:R893-912.
22. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens. 2004;17:167-171.
23. Jaimers EA, Nath KA, Raij L. Hydrogen peroxide downregulate IL-1-driven mesangial iNOS activity: implications for glomerulonephritis. Am J Physiol. 1997;272:F721-F728.
24. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Luscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension, Hypertension. 1998;31:499-504.
25. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998;31:342-348.
26. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, Takeshita A. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens. 2000;18:1795-1800.
27. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996;93:13176-13181.
28. Dusting GJ, Fennessy P, Yin ZL, Gurevich V. Nitric oxide in atherosclerosis: vascular protector or villain? Clin Exp Pharmacol Physiol Suppl. 1998;25:S34-S41.
29. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429-432.
30. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734-1737.
31. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.
32. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS. 3-Hydroxy-3-methylglutary CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephrology. Proc Natl Acad Sci USA. 2002;99:8301-8305.
33. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol. 2003;35:59-70.
34. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Ichiki T, Takehashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775.
35. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22:867-877.
36. Borghi C, Prandin M, Costa F, Bacchelli S, Degli-Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35:349-355.
37. Lee T, Su S, Tsai C. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40:67-73.
38. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
39. Ying L, Flamant M, Vandermeersch S, Boffa J, Chatziantoniou C, Dussaule J, Chansel D. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension. 2003;42:937-944.